De huidige medicamenteuze behandeling van de ziekte van Alzheimer

Bierer, L.M., Haroutunian, V., Gabriel, S., Knott, P.I., Carlin, L.S., Purohit, D.P., et al. (1995) Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem, 64, 749-760.

Burke, W.I., Roccaforte, W.H., Wengel, S.P., Bayer, B.L., Ranno, A.E., Willcockson, N.K. (1993). L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc, 41, 1219-1225.

Claus, 1.1., Ludwig, C., Mohr, E., Iuffra, M., Blin, I., Chase, T.N. (1991). Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology, 41, 570-574.

Croisile, B., Trillet, M., Fondarai, I., Laurent, B., Maugiere, F., Billardon, M. (1993). Long-term and high dose piracetam treatment of Alzheimer's disease. Neurology, 43, 301-305.

Eikelenboom, P., Zhan, S-S., Van GooI, W.A., Allsop, D. (1994). Inflammatory mechanisms in Alzheimer's disease. TIPS, 15,447-450.

Henderson, V.W., Paganini-Hill, A., Emanuel, C.K., Dunn, M.E., Buckwalter, G. (1994). Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol, 51, 896-900.

Hydra, A., Scheltens, Ph. (1994). Diagnositic criteria for vascular dementia. In: Leys D, Scheltens Ph. (red.) Vascular dementia. Current issues in neurodegenerative diseases, dl 6. Dordrecht, ICG Publications, 3-8.

Jonker, C., Scheltens, P., Loenen A.C. van. (1997). Nieuwe inzichten in de farmacotherapie. Ziekte van Alzheimer. Pharmaceutisch Weekblad, 132, 1108-1116.

Knapp, M.I., Knopman, D.S., Solomon, P.R., Pendleburry, W.W., Davis, C.S., Gracon, S.I., et al. (1994). A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA, 271, 985-991.

Lahiri, D.K., Lewis, S., Farlow, M.R. (1994). Tacrine alters the secretion of the beta-amyloid precursor protein in celllines. J Neurosc Res, 37, 777-787.

Leeuwen F.W. van, Kleijn D.P.V. de, Van den Hurk H.H., et al. (1998). Frameshift mutants of beta-amyloid precursor protein and ubiquitin- B in Alzheimer's and Down patients. Science, 279, 242-247.

Marcusson, I., Rother, M., Kittner, B., et al. (1997). A 12 month, randomized, placebocontrolled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord, 8, 320-328.

McGeer, P.L., Rogers, I. (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology, 42, 447-449.

Maller, H.I., Maurer, I., Saletu, B. (1994). Placebo-controlled trial ofthe xanthine derivate propentofylline. Pharmacopsychiatry, 27, 159-165.

Paganini-Hill, A., Henderson, V.W. (1994). Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol, 140, 256-261.

Rich, I.B., Rasmusson, D.X., Folstein, M.F., Carson, K.A., Kawas, C., Brandt, I. (1995). Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology, 45, 51-55.

Rogers, I., Kirby, L.C., Hempelman, S.R., Berry, D.L., McGeer, P.L., Kaszniak, A.W., et al. (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43, 1609-1611.

Rogers, S., Friedhoff, L. T., and the donepezil stidu group. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease. Dementia, 7, 293-303.

Rogers, S.L., Farlow, M.R., Mohs, R., et al. (1998). A 24 week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, aangeboden.

Sano, M., Ernesto, C., Thomas, R.G., et al. (1997). A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. N Engl J Med, 336, 1216-1222.

Schneider, L.S., Farlow, M.R., Henderson, V.W., Pogoda, I.M. (1995). Estrogen replacement therapy may enhance response to tacrine in women with Alzheimer's disease. Neurology, 45(suppl), A288.

Schneider, L.S., Olin, I.T., Pawluczyk, S. (1993). A double blind crossover pilot study of l-deprenyl (selegiline) Regular with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry, 150,321-323.